Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

(2013) S Bellone et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody

(2010) Christine E. Richter et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer

(2010) Stefania Bellone et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

(2009) M. Munz et al.   CANCER RESEARCH

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody

(2008) Shoshana Morecki et al.   EXPERIMENTAL HEMATOLOGY

Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM

(2008) Markus Munz   Frontiers in Bioscience-Landmark